by Michael Boyd | Jul 25, 2023 | Publications
There is a recognized need to improve the application of epidemiologic data in human health risk assessment especially for understanding and characterizing risks from environmental and occupational exposures. Although there is uncertainty associated with the results...
by Michael Boyd | Jul 25, 2023 | Publications
To place endocrine screening results in the context of potency and human exposure, we propose a method that entails (1) calculating a benchmark dose for a response measured in an endocrine screen; (2) estimating the human urinary concentration (biomonitoring...
by Michael Boyd | Jul 25, 2023 | Publications
In 2009, companies began screening compounds using the US Environmental Protection Agency’s Endocrine Disruptor Screening Program (EDSP). EDSP has two tiers: Tier 1 includes 11 assays to identify compounds with potential endocrine activity. This article...
by Michael Boyd | Jul 25, 2023 | Publications
A wide variety of potentially endocrine-relevant endpoints were identified for mollusks, fish, amphibians, birds, and mammals, although the strength of the relationship between test endpoints and population-level effects was often uncertain. Furthermore, testing alone...
by Michael Boyd | Jul 25, 2023 | Publications
Because regulatory programs evaluate substances for their endocrine-disrupting properties, careful study design and data interpretation are needed to distinguish between responses that are truly endocrine specific and those that are not. This is particularly important...
Recent Comments